Our Mission
Quintessence Biosciences is working to improve the lives of cancer patients by developing new drugs based on EVade Ribonuclease technologies.
Spotlight
Lead Candidate, QBI-139
A Phase I trial of QBI-139 in cancer patients
with solid tumors is ongoing at the University of Wisconsin
Comprehensive Cancer Center (UWCCC)
in Madison.
Informtion about the trial can be found at www.clinicaltrials.gov
(Clinical Trials.gov Identifier: NCT00818831).
Potential enrollees can contact the UWCCC Cancer
Connect (800-622-8922; 608-262-5223; uwccc@uwccc.wisc.edu) for
information (Unique Protocol ID # CO 08912). Quintessence Biosciences
will not directly enroll patients. |
Latest News
3.26.2009
Patients Now Enrolling in Phase I Human Trial for
Quintessence Biosciences Cancer Drug, QBI-139 (PDF)
Quintessence Biosciences' presentation, Anti-cancer activity
of human ribonuclease conjugates with enhanced pharmacokinetic
profiles, provides data for conjugates made from the Company's
lead candidate QBI-139.
12.05.2008 Quintessence
Biosciences Cancer Drug, QBI-139, Clears FDA Review to Start
Phase I human trial (PDF)
The Company announced today that the Food and Drug Administration
has cleared its Investigational New Drug (IND) application for
the first of the Company's EVade™ Ribonuclease drug candidates,
called QBI-139.
10.06.2008Quintessence
Biosciences, Inc. Awarded Federal Contract (PDF)Quintessence
Biosciences, Inc .announced the receipt of a Phase 1 Small Business
Innovation Research contract from the National Cancer Institute
to support the development of next generation drugs based on
the EVade™ Ribonuclease technology.
|
